osteoporosis and therapy Archives - ACR Meeting Abstracts

Abstract Number: 1282 • ACR/ARHP Annual Meeting 2015
Persistence with Osteoporosis Therapies in Postmenopausal Women in a Large US National Health Plan
Benjamin Chastek¹, Lung-I Cheng², John C. White³, Leslie Spangler⁴, Darshan Mehta⁵ and Richard Barron⁶, ¹Optum Insight, Eden Prairie, MN, ²Amgen, Thousand Oaks, CA, ³Optum Life Sciences, Eden Prairie, MN, ⁴Amgen Inc., Thousand Oaks, CA, ⁵University of Southern California, Los Angeles, CA, ⁶Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Persistence and compliance with oral osteoporosis therapies are generally suboptimal; however, limited persistence data exist for newer injectable therapies that have become available in…
Abstract Number: 1237 • ACR/ARHP Annual Meeting 2013
Denosumab Leads To Significantly Greater Increases In Bone Mineral Density Than Ibandronate and Risedronate In Postmenopausal Women At High Risk For Fracture Who Were Previously Treated With An Oral Bisphosphonate
Jacques P. Brown¹, Michael A. Bolognese², Pei-Ran Ho³, Jesse Hall³, Christian Roux⁴, Henry G. Bone⁵, Sydney Bonnick⁶, Joop van den Bergh⁷, Irene Ferreira⁸, Prayashi Ghelani⁹, Paula Dakin³, Rachel B. Wagman³ and Chris Recknor¹⁰, ¹CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ²Bethesda Health Research Center, Bethesda, MD, ³Amgen Inc., Thousand Oaks, CA, ⁴Paris Descartes University, Paris, France, ⁵Michigan Bone and Mineral Clinic, Detroit, MI, ⁶Clinical Research Center of North Texas, Denton, TX, ⁷VieCuri Medical Centre and Maastricht University, Venlo, Netherlands, ⁸Amgen Inc., Cambridge, United Kingdom, ⁹Ovatech Solutions, London, United Kingdom, ¹⁰United Osteoporosis Centers, Gainesville, GA
Denosumab Leads to Significantly Greater Increases in Bone Mineral Density Than Ibandronate and Risedronate in Postmenopausal Women at High Risk for Fracture Who Were Previously…

Abstracts tagged "osteoporosis and therapy"

Persistence with Osteoporosis Therapies in Postmenopausal Women in a Large US National Health Plan

Denosumab Leads To Significantly Greater Increases In Bone Mineral Density Than Ibandronate and Risedronate In Postmenopausal Women At High Risk For Fracture Who Were Previously Treated With An Oral Bisphosphonate